Vima Therapeutics Raises $100M to Advance Oral Therapy for Movement Disorders
Key Insights
Vima Therapeutics (search) secured $100 million in funding to develop VIM0423 (search), an oral combination therapy targeting muscarinic cholinergic receptors (search) for movement disorders.
The company plans to initiate mid-stage clinical trials for Parkinson's disease (search) and dystonia (search), with results expected in 2027.
VIM0423 (search) addresses a significant unmet need, as approximately 160,000 Americans with isolated dystonia (search) currently lack FDA-approved oral treatment options.
Vima Therapeutics (search) announced Wednesday it has raised $100 million to advance VIM0423 (search), an oral combination therapy designed to help patients with neurological movement disorders regain motor control. The funding positions the company to launch mid-stage clinical trials in Parkinson's disease (search) and dystonia (search), with results anticipated in 2027.
The biotechnology company, founded by Atlas Venture (search) more than three years ago, is targeting a significant unmet medical need in movement disorders. Vima estimates that approximately 160,000 people in the United States have isolated dystonia (search), a chronic and disabling neurological condition characterized by involuntary muscle contractions that worsen with movement. Dystonia also manifests as a symptom in other brain diseases, including Parkinson's disease (search).
Addressing Treatment Gaps
Current treatment options for dystonia (search) and Parkinson's disease (search) include medications like levodopa, Botox injections, and other therapies that reduce muscle stiffness. However, these treatments can lose effectiveness over time or cause prohibitive side effects. Critically, patients with isolated dystonia have no FDA-approved oral treatment options available.
"Often the problem with [neurology] is uncertainty about the mechanism, risk for later-stage failure," said Bernard Ravina, Vima's CEO, in an interview with BioPharma Dive. "That's one of the reasons we really like this: clear need and match of the biology here with clinical validation."
Novel Mechanism of Action
VIM0423 (search) works by selectively targeting muscarinic cholinergic receptors (search), which regulate various neurological functions including motor control. While older drugs targeting these receptors exist, such as trihexyphenidyl—a component of VIM0423—they are associated with poor tolerability. Vima's combination therapy is engineered to provide enhanced safety and improved pharmacological properties.
Leadership and Vision
Ravina, a neurologist by training, founded Vima with Atlas Venture (search) following previous leadership roles at brain-focused biotechnology companies Praxis Precision Medicines and Voyager Therapeutics. The company's name derives from the Greek term for "step" or "stride," reflecting its focus on movement disorders.
The substantial Series A funding round demonstrates investor confidence in Vima's approach to addressing movement disorders through targeted receptor modulation, positioning the company to advance its lead candidate through critical clinical development phases.